Press "Enter" to skip to content

Rafael Pharmaceuticals Enters into Out-Licensing Agreement with Ono Pharmaceutical to Accelerate Clinical Development and Commercialization of Cancer Drug Candidate CPI-613® (devimistat) in Japan and Other Asian Countries – GlobeNewswire

admin 0

Rafael Pharmaceuticals Enters into Out-Licensing Agreement with Ono Pharmaceutical to Accelerate Clinical Development and Commercialization of Cancer Drug Candidate CPI-613® (devimistat) in Japan and Other Asian Countries  GlobeNewswire

Cranbury, NJ, June 25, 2019 (GLOBE NEWSWIRE) — Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer …

“pancreatic cancer” – Google News

(Visited 5 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *